Scavenger receptor-A is a biomarker and effector of rheumatoid arthritis: A large-scale multicenter study.
Fanlei Hu, Xiang Jiang, Chunqing Guo...
https://pubmed.ncbi.nlm.nih.gov/32312978/Actively Recruiting
Led by Peking University People's Hospital · Updated on 2026-04-17
40
Participants Needed
1
Research Sites
30 weeks
Total Duration
Researchers are investigating the potential therapeutic effects of fucoidan, an inhibitor of scavenger receptor-A SR-A, in adults with active rheumatoid arthritis RA who have had an inadequate response to conventional treatments. RA is a chronic autoimmune disease marked by joint damage and autoantibody production, and elevated SR-A levels have been linked to disease progression. This multicenter, single-arm, open-label trial aims to provide original clinical data by enrolling 40 patients for a 12-week follow-up period to evaluate clinical symptoms, laboratory markers, and disease activity. Participants will continue their existing conventional RA treatments while taking 2000 mg of oral fucoidan twice daily for 12 weeks. Fucoidan is provided as size-0 gelatin capsules containing 1000 mg of fucoidan powder each. This add-on therapy will be systematically assessed throughout the treatment period to monitor its impact on disease progression and activity. Patients will undergo regular evaluations including clinical assessments and laboratory tests to measure disease activity and response to treatment. The primary outcome is the proportion of patients achieving the American College of Rheumatology 20% improvement criteria ACR20 at Week 12. Secondary outcomes include remission rates by Disease Activity Score in 28 joints using ESR, changes in clinical disease activity indices, and response rates according to other established RA criteria. Safety and adherence will also be monitored during the study period.
CONDITIONS
Fucoidan in the Treatment of Active Rheumatoid Arthritis
L
Liling Xu
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Peking University People's Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 weeks continuous treatment
Participants receive oral fucoidan capsules twice daily in addition to their stable conventional rheumatoid arthritis treatment.
Regular visits during the 12 weeks of treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Fanlei Hu, Xiang Jiang, Chunqing Guo...
https://pubmed.ncbi.nlm.nih.gov/32312978/Chia-Wei Yeh, Chia-Ju Shih, Tu-Chen Liu...
https://pubmed.ncbi.nlm.nih.gov/36307493/Aleksandra Konic Ristic, Sinead Ryan, Maha Attjioui...
https://pubmed.ncbi.nlm.nih.gov/37367662/Zhan-Guo Li
https://pubmed.ncbi.nlm.nih.gov/25599919/Peking University People's Hospital
Lead Sponsor